Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Candel Therapeutics ( (CADL) ).
On February 19, 2026, Candel Therapeutics announced a $100 million royalty-based funding agreement with funds managed by RTW Investments to support the potential U.S. launch of its lead candidate aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, contingent on future FDA marketing approval. Under the deal, RTW will receive tiered single-digit royalties on U.S. net sales of CAN-2409 up to a $250 million cap, while Candel, which estimated unaudited cash and cash equivalents of about $119.7 million as of December 31, 2025, strengthens its balance sheet with non-dilutive capital ahead of a planned biologics license application submission in the fourth quarter and positions itself for a first commercial entry in a prostate cancer segment that has seen limited innovation in two decades.
The transaction includes provisions for a buy-out option if Candel undergoes a change of control or sells CAN-2409 rights, allowing termination of the royalty agreement for specified payments up to the cap. The structure, which activates only upon regulatory approval and other closing conditions, underscores RTW’s confidence in the commercial potential of CAN-2409 following pivotal phase 3 data in early localized prostate cancer and aligns investor and company interests around execution of a U.S. launch strategy.
The most recent analyst rating on (CADL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and significant cash burn) despite a stronger, low-leverage balance sheet. Technicals are moderately favorable with price above major moving averages and positive momentum indicators. Valuation remains challenged due to negative earnings, while recent corporate events provide a modest positive offset via improved financing capacity and pipeline visibility.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit individualized systemic anti-tumor immune responses to help patients fight cancer. The company’s pipeline is built on adenovirus and herpes simplex virus gene-therapy platforms, led by aglatimagene besadenovec (CAN-2409) for localized prostate cancer, non-small cell lung cancer and pancreatic ductal adenocarcinoma, and linoserpaturev (CAN-3110) for recurrent high-grade glioma, alongside its HSV-based enLIGHTEN Discovery Platform for new viral immunotherapies for solid tumors.
On February 19, 2026, Candel Therapeutics announced a $100 million royalty-based funding agreement with funds managed by RTW Investments to support the potential U.S. launch of its lead candidate aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, contingent on future FDA marketing approval. Under the deal, RTW will receive tiered single-digit royalties on U.S. net sales of CAN-2409 up to a $250 million cap, while Candel, which estimated unaudited cash and cash equivalents of about $119.7 million as of December 31, 2025, strengthens its balance sheet with non-dilutive capital ahead of a planned biologics license application submission in the fourth quarter and positions itself for a first commercial entry in a prostate cancer segment that has seen limited innovation in two decades.
The transaction includes provisions for a buy-out option if Candel undergoes a change of control or sells CAN-2409 rights, allowing termination of the royalty agreement for specified payments up to the cap. The structure, which activates only upon regulatory approval and other closing conditions, underscores RTW’s confidence in the commercial potential of CAN-2409 following pivotal phase 3 data in early localized prostate cancer and aligns investor and company interests around execution of a U.S. launch strategy.
Average Trading Volume: 781,066
Technical Sentiment Signal: Buy
Current Market Cap: $309.1M
See more insights into CADL stock on TipRanks’ Stock Analysis page.